Monitor for any future conversion to Schedule 13D if Oyler shifts to activist stance, but this filing is a routine passive update with no immediate trading signal.
ONC drugs
ONC drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CEO John Oyler filed an amended Schedule 13G reporting beneficial ownership of 54,065,077 ordinary shares (3.6% of shares outstanding) as of September 30, 2026. The filing is a routine periodic update with no change in stake direction disclosed in the document, and it follows strong Q3 earnings reported eight days earlier.
Key Financial Metrics
Key Facts
- John Oyler beneficially owns 54,065,077 ordinary shares of BeOne Medicines Ltd.
- Stake represents 3.6% of 1,483,318,035 ordinary shares outstanding as of September 30, 2026.
- Ownership includes shares held directly, in trusts, retirement accounts, and options/RSUs exercisable within 60 days.
- Filing is an amendment to Schedule 13G, indicating no change in passive investor status.
- Filed on November 13, 2026, with a reporting date of September 30, 2026.
Financial Impact
No financial impact; CEO stake disclosure with no change in direction or material new information.
Risk Factors
- No change in stake direction disclosed; filing is a routine periodic amendment.
- No material new information beyond ownership breakdown.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001104659-26-127046 |
| Document: 0001104659-26-127046-index.html | 0001104659-26-127046 |
| Document: 0001104659-26-127046.txt | 0001104659-26-127046 |
Track record
27 reports on ONC
3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +12.55% at T+60 after the Aug 5, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Viewing Entry $416.54 Now $411.29 −1.26% settles Nov 23
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $419.98 Now $411.29 −2.07% settles Nov 18
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $417.33 to $411.29 Now $411.29 −1.45% ▼ −1.45% +0.25% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $406.96 to $416.54 Now $411.29 +1.06% ▲ +2.35% −0.24% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $387.25 to $415.96 Now $411.29 +6.21% ▲ +7.41% +4.12% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $377.78 to $419.98 Now $411.29 +8.87% ▲ +11.17% +12.08% vs SPY
- Oct 2, 20266w ago Insider Cluster Bearish 5/10 Entry $361.65 to $350.40 Now $411.29 −13.73% ▲ +3.11% +3.53% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $368.08 to $365.27 Now $411.29 +11.74% ▼ −0.76% +0.42% vs SPY
- Sep 10, 20269w ago Insider Cluster Neutral 3/10 Entry $346.51 to $350.84 Now $411.29 +18.69% ▲ +1.25% +1.47% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $358.26 to $353.83 Now $411.29 +14.80% ▼ −1.24% −0.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers